Healthy Adults; Cognitive Performance; Sleep Quality; Neuromuscular FunctionNCT07706283
Sex-Divergent Effects of Magnesium L-Threonate Supplementation on Sleep Quality, Cognitive Performance, and Neuromuscular Function in Healthy Adults
A study testing Magnesium L-threonate in people with Healthy Adults; Cognitive Performance; Sleep Quality; Neuromuscular Function, run by Barry University at 1 site in United States.
Trial summary
This study examined the effects of six weeks of magnesium L-threonate (MgT) supplementation on sleep quality, cognitive performance under experimentally induced mental fatigue, neuromuscular function, and psychophysiological outcomes in healthy adults. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Adults; Cognitive Performance; Sleep Quality; Neuromuscular Function
- What is being tested?
- Magnesium L-threonate
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 81 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Dec 2025to 19 Mar 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy male or female adults aged 18-45 years
- Free from diagnosed neurological, cardiovascular, metabolic, or psychiatric conditions
- Not currently taking medications or supplements known to influence cognitive or neuromuscular function
- Willing to maintain habitual diet, physical activity, and sleep routines throughout the study period
Who cannot join
- Pregnant or breastfeeding
- Diagnosed sleep disorder
- Initiated any new supplement or medication regimen within the past three months
- Failed to meet ≥85% supplementation adherence threshold during the study (post-enrollment exclusion)
- Technical data malfunction resulting in unrecoverable testing data (post-enrollment exclusion)
- Identified as a multivariate outlier (values exceeding ±3 SD from the group mean on primary outcomes; post-enrollment exclusion)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Sex-Divergent Effects of Magnesium L-Threonate Supplementation on Sleep Quality, Cognitive Performance Under Mental Fatigue, and Neuromuscular Function in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
This study examined the effects of six weeks of magnesium L-threonate (MgT) supplementation on sleep quality, cognitive performance under experimentally induced mental fatigue, neuromuscular function, and psychophysiological outcomes in healthy adults. Biological sex and weight status were examined as pre-specified moderating variables.
Read the detailed description
This study was a randomized, double-blind, placebo-controlled, parallel-group trial examining the effects of six weeks of magnesium L-threonate (MgT) supplementation on cognitive performance, mental fatigue, neuromuscular function, sleep quality, and psychophysiological outcomes in healthy adults. Biological sex and weight status were examined as pre-specified moderating variables given evidence for sex-specific differences in magnesium homeostasis and the elevated prevalence of magnesium inadequacy in individuals with overweight or obesity.
Participants:
Healthy male and female adults aged 18-45 years were recruited from a local university and surrounding community. Eighty-one participants were enrolled and randomized; the final analytic sample comprised 54 participants (MgT: n = 28; PLA: n = 26) following exclusions for non-adherence, technical data malfunction, and multivariate outlier removal. The sample was 59% female with a mean age of 23 ± 6 years and mean BMI of 26.7 ± 6.3 kg/m².
Intervention:
Participants assigned to the intervention group consumed 2 g·day-¹ of magnesium L-threonate (Magtein®; AIDP Inc., City of Industry, CA, USA) divided into two daily doses (morning and evening) for six weeks. Participants assigned to the placebo group consumed visually identical capsules containing rice powder (2 g·day-¹) on the same dosing schedule. Supplement compliance was assessed via capsule count at study conclusion; participants demonstrating less than 85% adherence were excluded from the final analytic sample.
Testing Procedures:
Participants completed identical testing sessions at baseline (Week 0) and following six weeks of supplementation (Week 6). All sessions were conducted at the same time of day for each participant to minimize circadian variability. Prior to each session, participants were instructed to abstain from caffeine for at least 12 hours, alcohol for 24 hours, and strenuous exercise for 24 hours.
Testing was conducted in a standardized order as follows:
Psychophysiological Questionnaires: Participants completed the Pittsburgh Sleep Quality Index (PSQI; 0-21 scale), Perceived Stress Scale (PSS), State-Trait Anxiety Inventory (STAI; state and trait subscales), and Visual Analog Scale for Fatigue (VAS-F; 0-100 mm) prior to any physical or cognitive testing.
Neuromuscular Assessment - Pre-fatigue: Countermovement jump (CMJ) performance was assessed using dual force plates (VALD ForceDecks, VALD Performance, Brisbane, Australia). Variables of interest included jump height (cm), peak landing force (N), reactive strength index (m·s-¹), and concentric impulse (N·s).
Cognitive Battery - Pre-fatigue: Cognitive performance was assessed using a computerized battery administered via the SOMA platform (SOMA Technologies, Lucerne, Switzerland). The battery included four tasks: the Psychomotor Fatigue Test (PFTT), Incongruent Flanker Task, Incongruent Stroop Task, and Task-Switching Test. Primary cognitive outcomes included reaction time (RT; ms), processing speed (1000/RT; s-¹), coefficient of variation (%), and rate correct score (correct responses·s-¹) derived from each task.
Mental Fatigue Induction: Mental fatigue was induced via a standardized 20-minute time-load dual-back (TLDB) task. The VAS-F was administered immediately before and after the TLDB task to quantify changes in perceived fatigue. The NASA Task Load Index (NASA-TLX) was completed immediately following the TLDB task to assess subjective cognitive workload across six subscales: mental demand, physical demand, temporal demand, performance, effort, and frustration.
Cognitive Battery - Post-fatigue: The full cognitive battery was repeated immediately following the TLDB protocol to assess performance under conditions of experimentally induced cognitive fatigue.
Neuromuscular Assessment - Post-fatigue: CMJ testing was repeated following the post-fatigue cognitive battery to assess the effect of cognitive load on subsequent neuromuscular output.
Statistical Analysis All analyses were performed in R with statistical significance set at α = 0.05. Primary outcomes were analyzed across three structurally distinct approaches: (1) absolute outcomes and within-bout change scores (pre- to post-mental fatigue) at W0 and W6 were analyzed using linear mixed models with fixed effects of condition, time, the condition-by-time interaction, and a random intercept for participant; (2) six-week change scores (W6 - W0) were analyzed using ANOVA with fixed effects of condition, sex, weight status, and the corresponding two- and three-way interactions; and (3) the change in the within-bout mental fatigue response across the six-week period was analyzed using analogous ANOVA to isolate whether MgT altered the magnitude of the acute mental fatigue response over time. Significant interaction effects were further assessed using post hoc comparisons with Bonferroni-Holm adjustment. Unadjusted simple effects tests were conducted when omnibus interactions were significant but adjusted post hoc comparisons were not, and are reported as exploratory. All primary models were re-estimated following removal of values exceeding ±3 SD to evaluate robustness of findings.
- Being tested
- Magnesium L-threonate, Placebo
- Keywords
- magnesium L-threonate, mental fatigue, sleep quality, neuromuscular function, sex differences, countermovement jump, cognitive performance, ergogenic supplementation
- Medical subject headings
- Sleep Initiation and Maintenance Disorders, Mental Fatigue
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Magnesium L-threonateDietary supplement
Also called Magtein®
Magnesium L-threonate
PlaceboDietary supplement
Rice powder
| Study group | Role | What they receive |
|---|---|---|
| Magnesium L-Threonate (MgT) | Experimental | Participants consumed 2 g·day-¹ of magnesium L-threonate (Magtein®; AIDP Inc., City of Industry, CA, USA) once daily for six weeks. Receives: Dietary Supplement: Magnesium L-threonate |
| Placebo | Placebo comparator | Participants consumed visually identical capsules containing rice powder (1.4 g·day-¹) once daily for six weeks. Capsules were matched to the intervention in appearance and dosing schedule. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pittsburgh Sleep Quality Index (PSQI)
Subjective sleep quality assessed using the Pittsburgh Sleep Quality Index (PSQI; scored 0-21). Higher scores indicate poorer sleep quality. A score ≥5 indicates poor sleep quality.
Measured: Baseline (Week 0) and post-intervention (Week 6)
Flanker Task Reaction Time
Reaction time (ms) on the Incongruent Flanker Task assessed via computerized cognitive battery (SOMA platform). Lower values indicate faster processing.
Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after a 20-minute mental fatigue induction protocol at each visit
Countermovement Jump Height
Jump height (cm) assessed via dual force plates (VALD ForceDecks). Higher values indicate greater neuromuscular performance.
Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after a 20-minute mental fatigue induction protocol at each visit
Secondary outcomes (22)
Flanker Task Processing Speed
Processing speed (1000/RT; s-¹) on the Incongruent Flanker Task. Higher values indicate faster processing.
Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Flanker Task Rate Correct Score
Rate correct score (correct responses·s-¹) on the Incongruent Flanker Task. Higher values indicate better integrated speed-accuracy performance.
Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Flanker Task Coefficient of Variation
Intraindividual response variability (%) on the Incongruent Flanker Task. Lower values indicate more consistent performance.
Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Stroop Task Reaction Time
Reaction time (ms) on the Incongruent Stroop Task assessed via computerized cognitive battery. Lower values indicate faster processing.
Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Stroop Task Processing Speed
Processing speed (1000/RT; s-¹) on the Incongruent Stroop Task. Higher values indicate faster processing.
Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Stroop Task Rate Correct Score
Rate correct score (correct responses·s-¹) on the Incongruent Stroop Task. Higher values indicate better integrated speed-accuracy performance.
Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Psychomotor Fatigue Test Reaction Time
Reaction time (ms) on the Psychomotor Fatigue Test (PFTT). Lower values indicate faster psychomotor processing.
Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Psychomotor Fatigue Test Processing Speed
Processing speed (1000/RT; s-¹) on the PFTT. Higher values indicate faster psychomotor processing.
Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Psychomotor Fatigue Test Rate Correct Score
Rate correct score (correct responses·s-¹) on the PFTT. Higher values indicate better integrated speed-accuracy performance.
Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Task-Switching Test Reaction Time
Reaction time (ms) on the Task-Switching Test (TSWT). Lower values indicate faster cognitive flexibility.
Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Task-Switching Test Processing Speed
Processing speed (1000/RT; s-¹) on the TSWT. Higher values indicate faster cognitive flexibility.
Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Task-Switching Test Rate Correct Score
Rate correct score (correct responses·s-¹) on the TSWT. Higher values indicate better integrated speed-accuracy performance.
Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Time-Load Dual-Back Rate Correct Score
Rate correct score (correct responses·s-¹) on the 20-minute time-load dual-back (TLDB) mental fatigue induction task.
Measured: Baseline (Week 0) and post-intervention (Week 6)
Countermovement Jump Peak Landing Force
Peak landing force (N) assessed via dual force plates (VALD ForceDecks).
Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Countermovement Jump Reactive Strength Index
Reactive strength index (m·s-¹) assessed via dual force plates (VALD ForceDecks). Higher values indicate greater neuromuscular efficiency.
Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Countermovement Jump Concentric Impulse
Concentric impulse (N·s) assessed via dual force plates (VALD ForceDecks). Higher values indicate greater force application during the propulsive phase.
Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Pittsburgh Sleep Quality Index - Global Score Change
Six-week change in PSQI global score stratified by sex and weight status.
Measured: Change from baseline (Week 0) to post-intervention (Week 6)
Perceived Stress Scale (PSS)
Perceived psychological stress assessed using the 10-item Perceived Stress Scale (scored 0-40). Higher scores indicate greater perceived stress.
Measured: Baseline (Week 0) and post-intervention (Week 6)
State-Trait Anxiety Inventory - State Subscale (STAI-S)
State anxiety assessed using the STAI state subscale (scored 20-80). Higher scores indicate greater anxiety.
Measured: Baseline (Week 0) and post-intervention (Week 6)
State-Trait Anxiety Inventory - Trait Subscale (STAI-T)
Trait anxiety assessed using the STAI trait subscale (scored 20-80). Higher scores indicate greater dispositional anxiety.
Measured: Baseline (Week 0) and post-intervention (Week 6)
Visual Analog Scale for Fatigue (VAS-F)
Subjective fatigue assessed using a 100 mm visual analog scale. Higher scores indicate greater perceived fatigue.
Measured: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction at each visit
NASA Task Load Index (NASA-TLX)
Multidimensional subjective workload assessed across six subscales: mental demand, physical demand, temporal demand, performance, effort, and frustration (each scored 0-20; total scored 0-120). Higher scores indicate greater perceived workload.
Measured: Baseline (Week 0) and post-intervention (Week 6), assessed immediately following mental fatigue induction
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jul 2026
- Study start1 Dec 2025
- Primary completion19 Mar 2026
- Study completion19 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy Adults; Cognitive Performance; Sleep Quality; Neuromuscular FunctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 81 participants (actual)
Sponsor and investigators
- Lead sponsor
- Barry University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Antonella Schwarz, Barry University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07706283
- Sponsor's protocol ID
- 2368924-3
- Status last verified
- Jul 2026
- First submitted
- 11 Jul 2026
- Last updated
- 15 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Individual participant data may be made available upon reasonable request to the corresponding author, pending review of the proposed use and confirmation that appropriate data sharing agreements are in place.
Study at a glance
From the registry record, last updated by the sponsor on 15 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sex-Divergent Effects of Magnesium L-Threonate Supplementation on Sleep Quality, Cognitive Performance Under Mental Fatigue, and Neuromuscular Function in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial
- ClinicalTrials.gov ID
- NCT07706283
- Acronym / sponsor ID
- 2368924-3
- Keywords
- magnesium L-threonate, mental fatigue, sleep quality, neuromuscular function, sex differences, countermovement jump, cognitive performance, ergogenic supplementation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 81 participants (actual)
- Lead sponsor
- Barry UniversityUniversity, hospital or other
- Study start
- 1 Dec 2025 (actual)
- Primary completion
- 19 Mar 2026 (actual)
- Study completion
- 19 Mar 2026 (actual)
- First posted
- 15 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study examined the effects of six weeks of magnesium L-threonate (MgT) supplementation on sleep quality, cognitive performance under experimentally induced mental fatigue, neuromuscular function, and psychophysiological outcomes in healthy adults. Biological sex and weight status were examined as pre-specified moderating variables.
Detailed description
This study was a randomized, double-blind, placebo-controlled, parallel-group trial examining the effects of six weeks of magnesium L-threonate (MgT) supplementation on cognitive performance, mental fatigue, neuromuscular function, sleep quality, and psychophysiological outcomes in healthy adults. Biological sex and weight status were examined as pre-specified moderating variables given evidence for sex-specific differences in magnesium homeostasis and the elevated prevalence of magnesium inadequacy in individuals with overweight or obesity.
Participants:
Healthy male and female adults aged 18-45 years were recruited from a local university and surrounding community. Eighty-one participants were enrolled and randomized; the final analytic sample comprised 54 participants (MgT: n = 28; PLA: n = 26) following exclusions for non-adherence, technical data malfunction, and multivariate outlier removal. The sample was 59% female with a mean age of 23 ± 6 years and mean BMI of 26.7 ± 6.3 kg/m².
Intervention:
Participants assigned to the intervention group consumed 2 g·day-¹ of magnesium L-threonate (Magtein®; AIDP Inc., City of Industry, CA, USA) divided into two daily doses (morning and evening) for six weeks. Participants assigned to the placebo group consumed visually identical capsules containing rice powder (2 g·day-¹) on the same dosing schedule. Supplement compliance was assessed via capsule count at study conclusion; participants demonstrating less than 85% adherence were excluded from the final analytic sample.
Testing Procedures:
Participants completed identical testing sessions at baseline (Week 0) and following six weeks of supplementation (Week 6). All sessions were conducted at the same time of day for each participant to minimize circadian variability. Prior to each session, participants were instructed to abstain from caffeine for at least 12 hours, alcohol for 24 hours, and strenuous exercise for 24 hours.
Testing was conducted in a standardized order as follows:
Psychophysiological Questionnaires: Participants completed the Pittsburgh Sleep Quality Index (PSQI; 0-21 scale), Perceived Stress Scale (PSS), State-Trait Anxiety Inventory (STAI; state and trait subscales), and Visual Analog Scale for Fatigue (VAS-F; 0-100 mm) prior to any physical or cognitive testing.
Neuromuscular Assessment - Pre-fatigue: Countermovement jump (CMJ) performance was assessed using dual force plates (VALD ForceDecks, VALD Performance, Brisbane, Australia). Variables of interest included jump height (cm), peak landing force (N), reactive strength index (m·s-¹), and concentric impulse (N·s).
Cognitive Battery - Pre-fatigue: Cognitive performance was assessed using a computerized battery administered via the SOMA platform (SOMA Technologies, Lucerne, Switzerland). The battery included four tasks: the Psychomotor Fatigue Test (PFTT), Incongruent Flanker Task, Incongruent Stroop Task, and Task-Switching Test. Primary cognitive outcomes included reaction time (RT; ms), processing speed (1000/RT; s-¹), coefficient of variation (%), and rate correct score (correct responses·s-¹) derived from each task.
Mental Fatigue Induction: Mental fatigue was induced via a standardized 20-minute time-load dual-back (TLDB) task. The VAS-F was administered immediately before and after the TLDB task to quantify changes in perceived fatigue. The NASA Task Load Index (NASA-TLX) was completed immediately following the TLDB task to assess subjective cognitive workload across six subscales: mental demand, physical demand, temporal demand, performance, effort, and frustration.
Cognitive Battery - Post-fatigue: The full cognitive battery was repeated immediately following the TLDB protocol to assess performance under conditions of experimentally induced cognitive fatigue.
Neuromuscular Assessment - Post-fatigue: CMJ testing was repeated following the post-fatigue cognitive battery to assess the effect of cognitive load on subsequent neuromuscular output.
Statistical Analysis All analyses were performed in R with statistical significance set at α = 0.05. Primary outcomes were analyzed across three structurally distinct approaches: (1) absolute outcomes and within-bout change scores (pre- to post-mental fatigue) at W0 and W6 were analyzed using linear mixed models with fixed effects of condition, time, the condition-by-time interaction, and a random intercept for participant; (2) six-week change scores (W6 - W0) were analyzed using ANOVA with fixed effects of condition, sex, weight status, and the corresponding two- and three-way interactions; and (3) the change in the within-bout mental fatigue response across the six-week period was analyzed using analogous ANOVA to isolate whether MgT altered the magnitude of the acute mental fatigue response over time. Significant interaction effects were further assessed using post hoc comparisons with Bonferroni-Holm adjustment. Unadjusted simple effects tests were conducted when omnibus interactions were significant but adjusted post hoc comparisons were not, and are reported as exploratory. All primary models were re-estimated following removal of values exceeding ±3 SD to evaluate robustness of findings.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Magnesium L-Threonate (MgT) | Experimental | Dietary Supplement: Magnesium L-threonateParticipants consumed 2 g·day-¹ of magnesium L-threonate (Magtein®; AIDP Inc., City of Industry, CA, USA) once daily for six weeks. |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboParticipants consumed visually identical capsules containing rice powder (1.4 g·day-¹) once daily for six weeks. Capsules were matched to the intervention in appearance and dosing schedule. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Healthy male or female adults aged 18-45 years
- Free from diagnosed neurological, cardiovascular, metabolic, or psychiatric conditions
- Not currently taking medications or supplements known to influence cognitive or neuromuscular function
- Willing to maintain habitual diet, physical activity, and sleep routines throughout the study period
Key exclusion criteria (6 listed)
- Pregnant or breastfeeding
- Diagnosed sleep disorder
- Initiated any new supplement or medication regimen within the past three months
- Failed to meet ≥85% supplementation adherence threshold during the study (post-enrollment exclusion)
- Technical data malfunction resulting in unrecoverable testing data (post-enrollment exclusion)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Magnesium L-threonateAlso: Magtein®Magnesium L-threonate | Dietary supplement | Magnesium L-Threonate (MgT) |
| PlaceboRice powder | Dietary supplement | Placebo |
Primary outcome
Pittsburgh Sleep Quality Index (PSQI)
Time frame: Baseline (Week 0) and post-intervention (Week 6)
Subjective sleep quality assessed using the Pittsburgh Sleep Quality Index (PSQI; scored 0-21). Higher scores indicate poorer sleep quality. A score ≥5 indicates poor sleep quality.
Flanker Task Reaction Time
Time frame: Baseline (Week 0) and post-intervention (Week 6), assessed before and after a 20-minute mental fatigue induction protocol at each visit
Reaction time (ms) on the Incongruent Flanker Task assessed via computerized cognitive battery (SOMA platform). Lower values indicate faster processing.
Countermovement Jump Height
Time frame: Baseline (Week 0) and post-intervention (Week 6), assessed before and after a 20-minute mental fatigue induction protocol at each visit
Jump height (cm) assessed via dual force plates (VALD ForceDecks). Higher values indicate greater neuromuscular performance.
22 secondary outcomes
Flanker Task Processing Speed
Time frame: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Flanker Task Rate Correct Score
Time frame: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Flanker Task Coefficient of Variation
Time frame: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Stroop Task Reaction Time
Time frame: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Stroop Task Processing Speed
Time frame: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Stroop Task Rate Correct Score
Time frame: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Psychomotor Fatigue Test Reaction Time
Time frame: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Psychomotor Fatigue Test Processing Speed
Time frame: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Psychomotor Fatigue Test Rate Correct Score
Time frame: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Task-Switching Test Reaction Time
Time frame: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Task-Switching Test Processing Speed
Time frame: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Task-Switching Test Rate Correct Score
Time frame: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Time-Load Dual-Back Rate Correct Score
Time frame: Baseline (Week 0) and post-intervention (Week 6)
Countermovement Jump Peak Landing Force
Time frame: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Countermovement Jump Reactive Strength Index
Time frame: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Countermovement Jump Concentric Impulse
Time frame: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction
Pittsburgh Sleep Quality Index - Global Score Change
Time frame: Change from baseline (Week 0) to post-intervention (Week 6)
Perceived Stress Scale (PSS)
Time frame: Baseline (Week 0) and post-intervention (Week 6)
State-Trait Anxiety Inventory - State Subscale (STAI-S)
Time frame: Baseline (Week 0) and post-intervention (Week 6)
State-Trait Anxiety Inventory - Trait Subscale (STAI-T)
Time frame: Baseline (Week 0) and post-intervention (Week 6)
Visual Analog Scale for Fatigue (VAS-F)
Time frame: Baseline (Week 0) and post-intervention (Week 6), assessed before and after mental fatigue induction at each visit
NASA Task Load Index (NASA-TLX)
Time frame: Baseline (Week 0) and post-intervention (Week 6), assessed immediately following mental fatigue induction
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jul 2026.
- Individual participant dataSharing planned: Undecided. Individual participant data may be made available upon reasonable request to the corresponding author, pending review of the proposed use and confirmation that appropriate data sharing agreements are in place.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Magnesium L-threonate in people with Healthy Adults; Cognitive Performance; Sleep Quality; Neuromuscular Function, run by Barry University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pittsburgh Sleep Quality Index (PSQI) (time frame: Baseline (Week 0) and post-intervention (Week 6)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2026; AzTrials last refreshed its copy on 8 Nov 2026.